Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about HYFT, unsubscribe in one click. Privacy
HYFT holds $7.6M in cash and short-term investments and burns about $3.1M/quarter from operations, an estimated runway of 7.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
We do not have sufficient cash reserves to fund our operations for the next twelve months, which raises substantial doubt about our ability to continue as a going concern.20-F, Jul 2026
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HYFT files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HYFT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →